AR099379A1 - Compuestos tricíclicos como agentes antineoplásicos - Google Patents
Compuestos tricíclicos como agentes antineoplásicosInfo
- Publication number
- AR099379A1 AR099379A1 ARP140104912A ARP140104912A AR099379A1 AR 099379 A1 AR099379 A1 AR 099379A1 AR P140104912 A ARP140104912 A AR P140104912A AR P140104912 A ARP140104912 A AR P140104912A AR 099379 A1 AR099379 A1 AR 099379A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- alkyl
- cycloalkyl
- hydrogen
- heteroaryl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 229940034982 antineoplastic agent Drugs 0.000 title 1
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 16
- 229910052739 hydrogen Inorganic materials 0.000 abstract 10
- 239000001257 hydrogen Substances 0.000 abstract 10
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 10
- 125000000623 heterocyclic group Chemical group 0.000 abstract 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 6
- 125000001072 heteroaryl group Chemical group 0.000 abstract 6
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 150000002367 halogens Chemical class 0.000 abstract 5
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 5
- 125000003107 substituted aryl group Chemical group 0.000 abstract 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 125000005017 substituted alkenyl group Chemical group 0.000 abstract 2
- 125000004426 substituted alkynyl group Chemical group 0.000 abstract 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 abstract 1
- 108010081348 HRT1 protein Hairy Proteins 0.000 abstract 1
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000005415 substituted alkoxy group Chemical group 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Steroid Compounds (AREA)
Abstract
Compuestos tricíclicos, composiciones aceptables desde el punto de vista farmacéutico que comprenden compuestos de la presente y métodos para usar esas composiciones en el tratamiento de diversos trastornos. Reivindicación 1: Un compuesto caracterizado porque tiene la fórmula (1) en donde: A es heterociclo opcionalmente sustituido o heteroarilo opcionalmente sustituido, en donde los sustituyentes son uno o más R; R es independientemente uno o más hidrógeno, halógeno, haloalquilo, hidroxialquilo, CN, CF₃, CH₂F, CHF₂, C₁₋₆ alquilo opcionalmente sustituido, C₁₋₆ alcoxi opcionalmente sustituido, C₃₋₆ cicloalquilo opcionalmente sustituido, heterociclo opcionalmente sustituido, -OR⁴, -CONR³R⁴, -NR³R⁴, NR³R⁴C₁₋₆ alquil-, -NR⁶OCOR³, -NR⁶COR³, NR⁶COR³C₁₋₆ alquil-, -NR⁶CO₂R³, NR⁶CO₂R³C₁₋₆ alquil-, -NR⁶CONR³R⁴, -SO₂NR³R⁴, SO₂C₁₋₆ alquil-, -NR⁶SO₂NR³R⁴, -NR⁶SO₂R⁴ o NR⁶SO₂R⁴C₁₋₆ alquil-; X e Y se seleccionan independientemente de hidrógeno, C₁₋₆ alquilo opcionalmente sustituido, C₃₋₈ cicloalquilo opcionalmente sustituido, arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido o heterociclo opcionalmente sustituido; Z es hidrógeno, halógeno, -OH, C₁₋₆ alquilo, C₁₋₆ alcoxi, -NR³R⁴, -CONR³R⁴, -OCONR³R⁴, -NR⁶OCOR³, -NR⁶CONR³R⁴, -NR⁶SO₂NR³R⁴ o -NR⁶SO₂R⁴; R¹ es, independientemente en cada caso, uno o más hidrógeno, halógeno, -CN, -OR⁴, -NR³R⁴, -CONR³R⁴, -COOH, -OCONR³R⁴, -NR⁶OCOR³, -NR⁶CONR³R⁴, -NR⁶SO₂NR³R⁴, -NR⁶SO₂R⁴, C₁₋₆ alquilo opcionalmente sustituido, C₂₋₆ alquenilo opcionalmente sustituido, C₂₋₆ alquinilo opcionalmente sustituido, C₁₋₆ alcoxi opcionalmente sustituido, C₃₋₈ cicloalquilo opcionalmente sustituido, C₃₋₈ cicloalquil-C₁₋₆ alquilo opcionalmente sustituido, C₃₋₈ cicloalquil-CO- opcionalmente sustituido, C₃₋₈ cicloalquil-SO₂- opcionalmente sustituido, aril-C₁₋₆ alcoxi opcionalmente sustituido, C₃₋₈ cicloalquil-C₁₋₆ alcoxi opcionalmente sustituido, heterociclil-CO- opcionalmente sustituido, heterociclilo opcionalmente sustituido, C₁₋₆ alquil-SO₂- opcionalmente sustituido, C₁₋₆ alquilo-NR⁶SO₂- opcionalmente sustituido, heterociclo-NR⁶SO₂- opcionalmente sustituido, C₁₋₆ alquil-NR⁶SO₂- opcionalmente sustituido o heterociclo-NR⁶SO₂- opcionalmente sustituido; R² es hidrógeno, halógeno, -CN, OH, -CONR³R⁴, -NR⁶COOR⁴, -NR⁶CONR³R⁴, -NR⁶COR⁴, -NR⁶SO₂R⁵, -SO₂NR³R⁴, -NR⁶SO₂NR³R⁴, C₁₋₆ alquilo opcionalmente sustituido, C₃₋₈ cicloalquilo opcionalmente sustituido, C₁₋₆ alcoxi opcionalmente sustituido, arilo opcionalmente sustituido, C₁₋₆ alquil-SO₂- opcionalmente sustituido, aril-SO₂ opcionalmente sustituido, heteroarilo opcionalmente sustituido o heterociclo opcionalmente sustituido; R³ es hidrógeno, C₁₋₆ alquilo opcionalmente sustituido, C₃₋₈ cicloalquilo opcionalmente sustituido, C₂₋₆ alquenilo opcionalmente sustituido, C₂₋₆ alquinilo opcionalmente sustituido, ciano-C₁₋₆ alquilo, hidroxi-C₁₋₆ alquilo, arilo opcionalmente sustituido, aril-C₁₋₆ alquilo opcionalmente sustituido, ariloxi-C₁₋₆ alquilo opcionalmente sustituido, C₁₋₆ alquil-SO₂- opcionalmente sustituido, heterociclilo opcionalmente sustituido, heterociclil-C₁₋₆ alquilo opcionalmente sustituido, heteroarilo opcionalmente sustituido o heteroaril-C₁₋₆ alquilo opcionalmente sustituido; R⁴ es hidrógeno, C₁₋₆ alquilo opcionalmente sustituido o C₃₋₈ cicloalquilo opcionalmente sustituido; o R³ y R⁴ pueden tomarse junto con el átomo de nitrógeno al que están unidos para formar un C₄₋₈ heteroarilo opcionalmente sustituido o un anillo C₄₋₈ heterocíclico; R⁵ es hidrógeno, C₁₋₆ alquilo opcionalmente sustituido, C₃₋₈ cicloalquilo opcionalmente sustituido, C₂₋₆ alquenilo opcionalmente sustituido, C₂₋₆ alquinilo opcionalmente sustituido, ciano-C₁₋₆ alquilo, hidroxi-C₁₋₆ alquilo, arilo opcionalmente sustituido, aril-C₁₋₆ alquilo opcionalmente sustituido, ariloxi-C₁₋₆ alquilo opcionalmente sustituido, C₁₋₆ alquil-SO₂- opcionalmente sustituido, heterociclilo opcionalmente sustituido, heterociclil-C₁₋₆ alquilo opcionalmente sustituido, heteroarilo opcionalmente sustituido o heteroaril-C₁₋₆ alquilo opcionalmente sustituido; R⁶ es hidrógeno o C₁₋₆ alquilo opcionalmente sustituido; R⁷ es hidrógeno, C₁₋₆ alquilo opcionalmente sustituido, -OR⁴, CN o halógeno; y/o una sal, un tautómero o un estereoisómero de aquel aceptables desde el punto de vista farmacéutico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361920500P | 2013-12-24 | 2013-12-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR099379A1 true AR099379A1 (es) | 2016-07-20 |
Family
ID=52293305
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140104912A AR099379A1 (es) | 2013-12-24 | 2014-12-23 | Compuestos tricíclicos como agentes antineoplásicos |
| ARP210103062A AR123996A2 (es) | 2013-12-24 | 2021-11-03 | Compuestos tricíclicos novedosos como agentes antineoplásicos |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210103062A AR123996A2 (es) | 2013-12-24 | 2021-11-03 | Compuestos tricíclicos novedosos como agentes antineoplásicos |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US20160318928A1 (es) |
| EP (2) | EP3087071B1 (es) |
| JP (2) | JP6466456B2 (es) |
| KR (1) | KR102457145B1 (es) |
| CN (2) | CN108558871B (es) |
| AR (2) | AR099379A1 (es) |
| AU (1) | AU2014369982B2 (es) |
| BR (1) | BR112016013744B1 (es) |
| CA (1) | CA2934953C (es) |
| CL (1) | CL2016001629A1 (es) |
| CY (2) | CY1121076T1 (es) |
| DK (2) | DK3087071T3 (es) |
| EA (2) | EA201990240A1 (es) |
| ES (2) | ES2857848T3 (es) |
| HR (2) | HRP20181849T1 (es) |
| HU (2) | HUE054183T2 (es) |
| IL (1) | IL246359B (es) |
| LT (2) | LT3087071T (es) |
| MA (1) | MA39211B1 (es) |
| MX (1) | MX369491B (es) |
| MY (1) | MY176489A (es) |
| NZ (1) | NZ722326A (es) |
| PE (1) | PE20160844A1 (es) |
| PH (1) | PH12016500953A1 (es) |
| PL (2) | PL3087071T3 (es) |
| PT (2) | PT3087071T (es) |
| RS (2) | RS61479B1 (es) |
| SG (1) | SG11201605097SA (es) |
| SI (2) | SI3087071T1 (es) |
| SM (2) | SMT202100165T1 (es) |
| TN (1) | TN2016000238A1 (es) |
| TW (2) | TWI726544B (es) |
| UY (1) | UY35916A (es) |
| WO (1) | WO2015100282A1 (es) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105189488B (zh) | 2013-02-27 | 2018-07-24 | 百时美施贵宝公司 | 用作溴区结构域抑制剂的咔唑化合物 |
| RU2016122654A (ru) | 2013-11-08 | 2017-12-14 | Дана-Фарбер Кэнсер Инститьют, Инк. | Комбинированная терапия злокачественной опухоли с использованием ингибиторов бромодоменового и экстратерминального (вет) белка |
| MA39211B1 (fr) * | 2013-12-24 | 2019-01-31 | Bristol Myers Squibb Co | Composés tricycliques comme agents anti-cancers |
| US9458156B2 (en) | 2014-12-23 | 2016-10-04 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
| WO2015131005A1 (en) * | 2014-02-28 | 2015-09-03 | The Regents Of The University Of Michigan | 9h-pyrimido[4,5-b]indoles and related analogs as bet bromodomain inhibitors |
| US9725449B2 (en) | 2015-05-12 | 2017-08-08 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
| ES2770349T3 (es) | 2015-05-12 | 2020-07-01 | Bristol Myers Squibb Co | Compuestos de 5H-pirido[3,2-b]indol como agentes antineoplásicos |
| HK1248115A1 (zh) | 2015-07-16 | 2018-10-12 | Bioxcel Therapeutics, Inc. | 一种使用免疫调节治疗癌症的新颖方法 |
| KR20180081507A (ko) * | 2015-10-02 | 2018-07-16 | 다나-파버 캔서 인스티튜트 인크. | 브로모도메인 저해제와 관문 차단의 조합 요법 |
| WO2017124936A1 (zh) * | 2016-01-20 | 2017-07-27 | 宁波文达医药科技有限公司 | 作为布罗莫区结构域抑制剂的咔啉衍生物 |
| WO2017124934A1 (zh) * | 2016-01-20 | 2017-07-27 | 宁波文达医药科技有限公司 | 作为布罗莫区结构域抑制剂的含膦咔啉衍生物 |
| EP3412669A4 (en) * | 2016-02-05 | 2019-09-04 | Chia Tai Tianqing Pharmaceutical Group Co.,Ltd | TRICYCLIC COMPOUND FOR PROTEIN INHIBITOR CONTAINING BROMODOMAINE AND PREPARATION, PHARMACEUTICAL COMPOSITION AND USE THEREOF |
| KR102845317B1 (ko) | 2016-03-01 | 2025-08-13 | 코어셉트 쎄라퓨틱스 인코포레이티드 | 체크포인트 억제제를 강화시키기 위한 글루코코르티코이드 수용체 조정제의 용도 |
| US10150754B2 (en) * | 2016-04-19 | 2018-12-11 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| RU2019117356A (ru) | 2016-11-10 | 2020-12-10 | Лосинь Фармасьютикал (Шанхай) Ко., Лтд. | Азотсодержащее макроциклическое соединение, способ его получения, фармацевтическая композиция и применение |
| CN106905347B (zh) * | 2017-04-18 | 2019-04-16 | 四川大学 | Brd4抑制剂及其在肿瘤治疗药物中的应用 |
| CN111356695B (zh) * | 2017-10-27 | 2022-12-30 | 北京加科思新药研发有限公司 | 新的三环化合物 |
| EP3814352A4 (en) | 2018-06-25 | 2022-03-30 | Jacobio Pharmaceuticals Co., Ltd. | TRICYCLIC COMPOUNDS |
| CN108840868B (zh) * | 2018-08-01 | 2019-10-18 | 上海山的实业有限公司 | 具有抗肿瘤活性的吲哚并吡啶酮类化合物的制备方法及应用 |
| US11234971B2 (en) | 2018-12-19 | 2022-02-01 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| WO2020132046A1 (en) | 2018-12-19 | 2020-06-25 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| CN113544129B (zh) * | 2019-04-04 | 2024-07-23 | 上海华汇拓医药科技有限公司 | 三环类化合物制备方法及其在医药领域的应用 |
| CN110003204B (zh) * | 2019-04-30 | 2020-08-11 | 上海勋和医药科技有限公司 | 一种bet蛋白抑制剂、其制备方法及用途 |
| US10947253B2 (en) | 2019-08-05 | 2021-03-16 | Ankh Life Sciences Limited | Fused polycyclic dimers |
| AU2020360170A1 (en) | 2019-09-30 | 2022-05-19 | Kyowa Kirin Co., Ltd. | Bet degrader |
| US12129265B2 (en) | 2020-07-21 | 2024-10-29 | Ankh Life Sciences Limited | Therapeutic agents and uses thereof |
| JP2024506260A (ja) * | 2021-01-22 | 2024-02-13 | ジンルイ バイオファーマ カンパニー リミテッド | 抗がん剤としての三環式化合物 |
| EP4297750A1 (en) * | 2021-02-25 | 2024-01-03 | Impact Biomedicines, Inc. | Use of a bet inhibitor alone or in combination with fedratinib or ruxolitinib for treating a hematological malignancy such as myelofibrosis |
| JP2024517608A (ja) * | 2021-05-06 | 2024-04-23 | ラジエル セラピューティクス エルティーディー． | 結晶性カルバゾール誘導体 |
| WO2024099441A1 (en) * | 2022-11-11 | 2024-05-16 | Jingrui Biopharma (Shandong) Co., Ltd. | Bromodomain and extra-terminal (bet) protein degrader |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993014080A1 (en) * | 1992-01-15 | 1993-07-22 | E.I. Du Pont De Nemours And Company | Bridged heterocyclic fungicides |
| CA2542682A1 (en) | 2003-10-18 | 2005-05-06 | Bayer Healthcare Ag | 5-substituted 2-(phenylmethyl) thio-4-phenyl-4h-1,2,4-triazole derivatives and related compounds as gaba-agonists for the treatment of urinary incontinence and related diseases |
| WO2005051318A2 (en) * | 2003-11-24 | 2005-06-09 | Viropharma Incorporated | Compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| ES2657443T3 (es) | 2005-03-25 | 2018-03-05 | Gitr, Inc. | Anticuerpos anti-GITR y usos de los mismos |
| GB0507298D0 (en) | 2005-04-11 | 2005-05-18 | Novartis Ag | Organic compounds |
| AU2006244068B9 (en) | 2005-05-10 | 2012-10-25 | Incyte Holdings Corporation | Modulators of indoleamine 2,3-dioxygenase and methods of using the same |
| KR101411165B1 (ko) | 2005-07-01 | 2014-06-25 | 메다렉스, 엘.엘.시. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체 |
| CA2634198C (en) | 2005-12-20 | 2014-06-03 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| US7696166B2 (en) | 2006-03-28 | 2010-04-13 | Albany Molecular Research, Inc. | Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| JP5319532B2 (ja) | 2006-09-19 | 2013-10-16 | インサイト・コーポレイション | インドールアミン２，３−ジオキシゲナーゼのモジュレーターとしてのｎ−ヒドロキシアミジノヘテロサイクル |
| UY30892A1 (es) | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| US8591886B2 (en) | 2007-07-12 | 2013-11-26 | Gitr, Inc. | Combination therapies employing GITR binding molecules |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| CA2932121A1 (en) | 2007-11-30 | 2009-06-11 | Newlink Genetics Corporation | Ido inhibitors |
| FR2927330B1 (fr) | 2008-02-07 | 2010-02-19 | Sanofi Aventis | Derives de 5,6-bisaryl-2-pyridine-carboxamide, leur preparation et leur application en therapeutique comme antagonistes des recepteurs a l'urotensine ii |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| WO2010077634A1 (en) | 2008-12-09 | 2010-07-08 | Genentech, Inc. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| JP5557849B2 (ja) * | 2008-12-19 | 2014-07-23 | ブリストル−マイヤーズ スクイブ カンパニー | カルバゾールおよびカルボリンキナーゼ阻害剤 |
| CA2772613C (en) | 2009-09-03 | 2020-03-10 | Schering Corporation | Anti-gitr antibodies |
| US8722720B2 (en) | 2009-10-28 | 2014-05-13 | Newlink Genetics Corporation | Imidazole derivatives as IDO inhibitors |
| PL2949670T3 (pl) | 2009-12-10 | 2019-07-31 | F. Hoffmann-La Roche Ag | Przeciwciała wiążące się preferencyjnie z zewnątrzkomórkową domeną 4 ludzkiego CSF-1R i ich zastosowanie |
| EA201201191A1 (ru) | 2010-02-26 | 2013-04-30 | Бёрингер Ингельхайм Интернациональ Гмбх | 4-[циклоалкилокси(гетеро)ариламино]тиено[2,3-d]пиримидины, обладающие ингибирующей активностью по отношению к mnkl/mnk2, предназначенные для фармацевтических композиций |
| US9150656B2 (en) | 2010-03-04 | 2015-10-06 | Macrogenics, Inc. | Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof |
| US9221910B2 (en) | 2010-03-05 | 2015-12-29 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R |
| US9169323B2 (en) | 2010-03-05 | 2015-10-27 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R |
| TWI503323B (zh) * | 2010-03-29 | 2015-10-11 | Oncotherapy Science Inc | 三環化合物以及含此化合物之ｐｂｋ抑制劑 |
| AU2011248083B2 (en) | 2010-05-04 | 2015-09-10 | Five Prime Therapeutics, Inc. | Antibodies that bind CSF1R |
| EP2582698B1 (en) | 2010-06-16 | 2016-09-14 | Vitae Pharmaceuticals, Inc. | Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use |
| MX337040B (es) | 2010-09-09 | 2016-02-09 | Pfizer | Moleculas de union a 4-1bb. |
| EP3053925A1 (en) * | 2010-12-16 | 2016-08-10 | F. Hoffmann-La Roche AG | Tricyclic pi3k inhibitor compounds and methods of use |
| US8580399B2 (en) * | 2011-04-08 | 2013-11-12 | Universal Display Corporation | Substituted oligoazacarbazoles for light emitting diodes |
| NO2694640T3 (es) | 2011-04-15 | 2018-03-17 | ||
| PL2699264T3 (pl) | 2011-04-20 | 2018-08-31 | Medimmune, Llc | Przeciwciała i inne cząsteczki wiążące B7-H1 i PD-1 |
| US9991447B2 (en) * | 2011-09-28 | 2018-06-05 | Idemitsu Korea Co., Ltd. | Material for organic electroluminescent element, and organic electroluminescent element produced using same |
| EP2785375B1 (en) | 2011-11-28 | 2020-07-22 | Merck Patent GmbH | Anti-pd-l1 antibodies and uses thereof |
| CA2853889A1 (en) | 2011-12-15 | 2013-06-20 | F. Hoffmann-La Roche Ag | Antibodies against human csf-1r and uses thereof |
| BR112014018961A8 (pt) | 2012-02-06 | 2017-07-11 | Genentech Inc | Anticorpo isolado, anticorpo biespecífico, fragmento, ácido nucleico isolado, vetor, célula hospedeira, método de produção de anticorpos, composição farmacêutica, uso do anticorpo, método de tratamento, método de inibição e artigo industrializado |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| HK1208233A1 (en) | 2012-05-11 | 2016-02-26 | 戊瑞治疗有限公司 | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| EP2890398A4 (en) | 2012-08-31 | 2016-03-09 | Five Prime Therapeutics Inc | METHODS OF TREATING DISEASES WITH ANTIBODIES THAT BIND COLONY STIMULATING FACTOR RECEIVER 1 (CSF1R) |
| UA115576C2 (uk) * | 2012-12-06 | 2017-11-27 | Байєр Фарма Акцієнгезелльшафт | Похідні бензимідазолу як антагоністи ер4 |
| CN105189488B (zh) * | 2013-02-27 | 2018-07-24 | 百时美施贵宝公司 | 用作溴区结构域抑制剂的咔唑化合物 |
| US9492460B2 (en) * | 2013-02-27 | 2016-11-15 | Bristol-Myers Squibb Company | Carbazole compounds useful as bromodomain inhibitors |
| CN105377851B (zh) * | 2013-03-11 | 2018-07-20 | 密执安州立大学董事会 | Bet布罗莫结构域抑制剂和使用这些抑制剂的治疗方法 |
| MA39211B1 (fr) * | 2013-12-24 | 2019-01-31 | Bristol Myers Squibb Co | Composés tricycliques comme agents anti-cancers |
-
2014
- 2014-12-23 MA MA39211A patent/MA39211B1/fr unknown
- 2014-12-23 DK DK14824743.0T patent/DK3087071T3/da active
- 2014-12-23 EA EA201990240A patent/EA201990240A1/ru unknown
- 2014-12-23 PT PT14824743T patent/PT3087071T/pt unknown
- 2014-12-23 RS RS20210158A patent/RS61479B1/sr unknown
- 2014-12-23 RS RS20181319A patent/RS58014B1/sr unknown
- 2014-12-23 LT LTEP14824743.0T patent/LT3087071T/lt unknown
- 2014-12-23 MY MYPI2016702341A patent/MY176489A/en unknown
- 2014-12-23 PL PL14824743T patent/PL3087071T3/pl unknown
- 2014-12-23 EP EP14824743.0A patent/EP3087071B1/en active Active
- 2014-12-23 PE PE2016000945A patent/PE20160844A1/es unknown
- 2014-12-23 EP EP18192207.1A patent/EP3466949B1/en active Active
- 2014-12-23 PT PT181922071T patent/PT3466949T/pt unknown
- 2014-12-23 CN CN201810460901.7A patent/CN108558871B/zh active Active
- 2014-12-23 TN TN2016000238A patent/TN2016000238A1/en unknown
- 2014-12-23 EA EA201691070A patent/EA032469B1/ru not_active IP Right Cessation
- 2014-12-23 MX MX2016007928A patent/MX369491B/es active IP Right Grant
- 2014-12-23 NZ NZ72232614A patent/NZ722326A/en not_active IP Right Cessation
- 2014-12-23 TW TW108146502A patent/TWI726544B/zh active
- 2014-12-23 SM SM20210165T patent/SMT202100165T1/it unknown
- 2014-12-23 SG SG11201605097SA patent/SG11201605097SA/en unknown
- 2014-12-23 DK DK18192207.1T patent/DK3466949T3/da active
- 2014-12-23 HU HUE18192207A patent/HUE054183T2/hu unknown
- 2014-12-23 ES ES18192207T patent/ES2857848T3/es active Active
- 2014-12-23 AR ARP140104912A patent/AR099379A1/es active IP Right Grant
- 2014-12-23 SI SI201430891T patent/SI3087071T1/sl unknown
- 2014-12-23 LT LTEP18192207.1T patent/LT3466949T/lt unknown
- 2014-12-23 US US15/107,652 patent/US20160318928A1/en not_active Abandoned
- 2014-12-23 SI SI201431748T patent/SI3466949T1/sl unknown
- 2014-12-23 BR BR112016013744-2A patent/BR112016013744B1/pt active IP Right Grant
- 2014-12-23 HU HUE14824743A patent/HUE041719T2/hu unknown
- 2014-12-23 HR HRP20181849TT patent/HRP20181849T1/hr unknown
- 2014-12-23 PL PL18192207T patent/PL3466949T3/pl unknown
- 2014-12-23 UY UY0001035916A patent/UY35916A/es unknown
- 2014-12-23 JP JP2016542692A patent/JP6466456B2/ja active Active
- 2014-12-23 CA CA2934953A patent/CA2934953C/en active Active
- 2014-12-23 AU AU2014369982A patent/AU2014369982B2/en active Active
- 2014-12-23 ES ES14824743T patent/ES2698998T3/es active Active
- 2014-12-23 KR KR1020167019782A patent/KR102457145B1/ko active Active
- 2014-12-23 SM SM20180643T patent/SMT201800643T1/it unknown
- 2014-12-23 WO PCT/US2014/072031 patent/WO2015100282A1/en not_active Ceased
- 2014-12-23 CN CN201480076189.0A patent/CN106029663B/zh active Active
- 2014-12-23 TW TW103145061A patent/TWI736517B/zh active
-
2016
- 2016-05-24 PH PH12016500953A patent/PH12016500953A1/en unknown
- 2016-06-20 IL IL246359A patent/IL246359B/en active IP Right Grant
- 2016-06-23 CL CL2016001629A patent/CL2016001629A1/es unknown
-
2018
- 2018-12-04 CY CY181101293T patent/CY1121076T1/el unknown
-
2019
- 2019-01-09 JP JP2019002078A patent/JP6675501B2/ja active Active
-
2021
- 2021-02-08 HR HRP20210212TT patent/HRP20210212T8/hr unknown
- 2021-03-17 CY CY20211100226T patent/CY1124061T1/el unknown
- 2021-11-03 AR ARP210103062A patent/AR123996A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR099379A1 (es) | Compuestos tricíclicos como agentes antineoplásicos | |
| ES2669189T3 (es) | Compuestos de carbazol útiles como inhibidores del bromodominio | |
| AR089671A1 (es) | 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| AR098414A1 (es) | PIPERAZINAS DE PIRAZOLO SUSTITUIDO COMO INHIBIDORES DE CASEÍNA QUINASA 1 d/e | |
| AR104176A1 (es) | Inhibidores de ido (indolamina-2,3-dioxigenasa) | |
| AR105648A1 (es) | Métodos para la preparación de ácidos biliares y derivados de los mismos | |
| AR105845A1 (es) | Compuestos de heteroarilo bicíclicos fusionados como moduladores de la función irak4 | |
| AR110401A1 (es) | Derivados dihidropirimidina bicíclica-carboxamida como inhibidores de rho-quinasa | |
| AR096788A1 (es) | Compuestos tricíclicos de carboxamida como inhibidores potentes de rock | |
| AR103742A1 (es) | Derivados de trifluorometilpropanamida | |
| AR103232A1 (es) | ANTAGONISTAS DE TGFbR | |
| MX388321B (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos. | |
| AR107061A1 (es) | Heteroarilhidroxipirimidinonas como agonistas del receptor de apj | |
| AR100049A1 (es) | Derivados de dihidrotiazina y dihidrooxazina con actividad inhibidora de bace1 | |
| AR097866A1 (es) | Derivados de 4-azaindol | |
| AR099415A1 (es) | Benzoilfenil-formamidinas con actividad fungicida, sus composiciones agronómicas y su uso para el control de hongos fitopatogénicos de cultivos agrarios | |
| AR094496A1 (es) | Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas | |
| EA201600403A1 (ru) | N-ацилиминогетероциклические соединения | |
| PH12017501652A1 (en) | Kv1.3 inhibitors and their medical application | |
| AR090557A1 (es) | DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2 | |
| AR108864A1 (es) | Agentes antibacterianos | |
| AR100439A1 (es) | Derivados de carboxamida | |
| AR103582A1 (es) | Ciclopropabenzofuranil-piridopirazindionas | |
| AR096161A1 (es) | Derivados de triazina | |
| AR111252A1 (es) | Compuestos de isoxazol carboxamida y usos de los mismos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |